If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...

On Wednesday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.4 which represents a decrease of $-0.03 or -0.68% from the prior close of $4.43. The stock opened at $4.44 and touched a low ...

New York, New York-- (Newsfile Corp. - November 28, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, ...

On Monday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.28 which represents a decrease of $-0.21 or -4.68% from the prior close of $4.49. The stock opened at $4.47 and touched a low ...

Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District ...

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Humacyte, Inc. (NASDAQ ...

Humacyte, Inc. (HUMA) Securities Class Action: The complaint, filed on behalf of investors who purchased Humacyte securities between May 10, 2024, and October 17, 2024, claims that the company and its ...

DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...

As of November 25 at 4:00 PM EST. Market Open. DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally ...

When I first analyzed Humacyte in October 2022, its stock was trading at ~$4.65 a share and prospects looked encouraging for its then dubbed human acellular vessel (HAV) platform candidates.